FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128562958> ?p ?o ?g. }

• W3128562958 endingPage "534" @default.
• W3128562958 startingPage "534" @default.
• W3128562958 abstract "Magnetic resonance imaging (MRI) with targeted biopsy is an appealing alternative to systematic 12-core transrectal ultrasonography (TRUS) biopsy for prostate cancer diagnosis, but has yet to be widely adopted.To determine whether MRI with only targeted biopsy was noninferior to systematic TRUS biopsies in the detection of International Society of Urological Pathology grade group (GG) 2 or greater prostate cancer.This multicenter, prospective randomized clinical trial was conducted in 5 Canadian academic health sciences centers between January 2017 and November 2019, and data were analyzed between January and March 2020. Participants included biopsy-naive men with a clinical suspicion of prostate cancer who were advised to undergo a prostate biopsy. Clinical suspicion was defined as a 5% or greater chance of GG2 or greater prostate cancer using the Prostate Cancer Prevention Trial Risk Calculator, version 2. Additional criteria were serum prostate-specific antigen levels of 20 ng/mL or less (to convert to micrograms per liter, multiply by 1) and no contraindication to MRI.Magnetic resonance imaging-targeted biopsy (MRI-TB) only if a lesion with a Prostate Imaging Reporting and Data System (PI-RADS), v 2.0, score of 3 or greater was identified vs 12-core systematic TRUS biopsy.The proportion of men with a diagnosis of GG2 or greater cancer. Secondary outcomes included the proportion who received a diagnosis of GG1 prostate cancer; GG3 or greater cancer; no significant cancer but subsequent positive MRI results and/or GG2 or greater cancer detected on a repeated biopsy by 2 years; and adverse events.The intention-to-treat population comprised 453 patients (367 [81.0%] White, 19 [4.2%] African Canadian, 32 [7.1%] Asian, and 10 [2.2%] Hispanic) who were randomized to undergo TRUS biopsy (226 [49.9%]) or MRI-TB (227 [51.1%]), of which 421 (93.0%) were evaluable per protocol. A lesion with a PI-RADS score of 3 or greater was detected in 138 of 221 men (62.4%) who underwent MRI, with 26 (12.1%), 82 (38.1%), and 30 (14.0%) having maximum PI-RADS scores of 3, 4, and 5, respectively. Eighty-three of 221 men who underwent MRI-TB (37%) had a negative MRI result and avoided biopsy. Cancers GG2 and greater were identified in 67 of 225 men (30%) who underwent TRUS biopsy vs 79 of 227 (35%) allocated to MRI-TB (absolute difference, 5%, 97.5% 1-sided CI, -3.4% to ∞; noninferiority margin, -5%). Adverse events were less common in the MRI-TB arm. Grade group 1 cancer detection was reduced by more than half in the MRI arm (from 22% to 10%; risk difference, -11.6%; 95% CI, -18.2% to -4.9%).Magnetic resonance imaging followed by selected targeted biopsy is noninferior to initial systematic biopsy in men at risk for prostate cancer in detecting GG2 or greater cancers.ClinicalTrials.gov Identifier: NCT02936258." @default.
• W3128562958 created "2021-02-15" @default.
• W3128562958 creator A5002196476 @default.
• W3128562958 creator A5002447665 @default.
• W3128562958 creator A5008343293 @default.
• W3128562958 creator A5018803355 @default.
• W3128562958 creator A5023820252 @default.
• W3128562958 creator A5027990022 @default.
• W3128562958 creator A5038321597 @default.
• W3128562958 creator A5038617581 @default.
• W3128562958 creator A5042734712 @default.
• W3128562958 creator A5045505112 @default.
• W3128562958 creator A5046040598 @default.
• W3128562958 creator A5046401177 @default.
• W3128562958 creator A5046888497 @default.
• W3128562958 creator A5050196540 @default.
• W3128562958 creator A5056958406 @default.
• W3128562958 creator A5059619380 @default.
• W3128562958 creator A5078445671 @default.
• W3128562958 creator A5084519550 @default.
• W3128562958 creator A5087929642 @default.
• W3128562958 creator A5088388062 @default.
• W3128562958 date "2021-04-01" @default.
• W3128562958 modified "2023-10-16" @default.
• W3128562958 title "Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer" @default.
• W3128562958 cites W1494521255 @default.
• W3128562958 cites W1589956260 @default.
• W3128562958 cites W2061259677 @default.
• W3128562958 cites W2066784320 @default.
• W3128562958 cites W2081830150 @default.
• W3128562958 cites W2095011839 @default.
• W3128562958 cites W2139228734 @default.
• W3128562958 cites W2148673597 @default.
• W3128562958 cites W2153720432 @default.
• W3128562958 cites W2162489494 @default.
• W3128562958 cites W2287642617 @default.
• W3128562958 cites W2577453388 @default.
• W3128562958 cites W2602353650 @default.
• W3128562958 cites W2761239970 @default.
• W3128562958 cites W2766240872 @default.
• W3128562958 cites W2793905111 @default.
• W3128562958 cites W2884302925 @default.
• W3128562958 cites W2900548778 @default.
• W3128562958 cites W2901859788 @default.
• W3128562958 cites W2902806174 @default.
• W3128562958 cites W2944375285 @default.
• W3128562958 cites W2960844714 @default.
• W3128562958 cites W2982030915 @default.
• W3128562958 cites W2984399591 @default.
• W3128562958 cites W3001170150 @default.
• W3128562958 cites W3016483492 @default.
• W3128562958 cites W3023898905 @default.
• W3128562958 doi "https://doi.org/10.1001/jamaoncol.2020.7589" @default.
• W3128562958 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7863017" @default.
• W3128562958 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33538782" @default.
• W3128562958 hasPublicationYear "2021" @default.
• W3128562958 type Work @default.
• W3128562958 sameAs 3128562958 @default.
• W3128562958 citedByCount "87" @default.
• W3128562958 countsByYear W31285629582021 @default.
• W3128562958 countsByYear W31285629582022 @default.
• W3128562958 countsByYear W31285629582023 @default.
• W3128562958 crossrefType "journal-article" @default.
• W3128562958 hasAuthorship W3128562958A5002196476 @default.
• W3128562958 hasAuthorship W3128562958A5002447665 @default.
• W3128562958 hasAuthorship W3128562958A5008343293 @default.
• W3128562958 hasAuthorship W3128562958A5018803355 @default.
• W3128562958 hasAuthorship W3128562958A5023820252 @default.
• W3128562958 hasAuthorship W3128562958A5027990022 @default.
• W3128562958 hasAuthorship W3128562958A5038321597 @default.
• W3128562958 hasAuthorship W3128562958A5038617581 @default.
• W3128562958 hasAuthorship W3128562958A5042734712 @default.
• W3128562958 hasAuthorship W3128562958A5045505112 @default.
• W3128562958 hasAuthorship W3128562958A5046040598 @default.
• W3128562958 hasAuthorship W3128562958A5046401177 @default.
• W3128562958 hasAuthorship W3128562958A5046888497 @default.
• W3128562958 hasAuthorship W3128562958A5050196540 @default.
• W3128562958 hasAuthorship W3128562958A5056958406 @default.
• W3128562958 hasAuthorship W3128562958A5059619380 @default.
• W3128562958 hasAuthorship W3128562958A5078445671 @default.
• W3128562958 hasAuthorship W3128562958A5084519550 @default.
• W3128562958 hasAuthorship W3128562958A5087929642 @default.
• W3128562958 hasAuthorship W3128562958A5088388062 @default.
• W3128562958 hasBestOaLocation W31285629581 @default.
• W3128562958 hasConcept C121608353 @default.
• W3128562958 hasConcept C126322002 @default.
• W3128562958 hasConcept C126838900 @default.
• W3128562958 hasConcept C143409427 @default.
• W3128562958 hasConcept C2775934546 @default.
• W3128562958 hasConcept C2776235491 @default.
• W3128562958 hasConcept C2780002838 @default.
• W3128562958 hasConcept C2780192828 @default.
• W3128562958 hasConcept C2781217009 @default.
• W3128562958 hasConcept C71924100 @default.
• W3128562958 hasConceptScore W3128562958C121608353 @default.
• W3128562958 hasConceptScore W3128562958C126322002 @default.
• W3128562958 hasConceptScore W3128562958C126838900 @default.
• W3128562958 hasConceptScore W3128562958C143409427 @default.

• next